valneva logo

VALNEVA and Adimmune partner to commercialize Japanese Encephalitis vaccine in Taiwan

In Press Releases by Vaccine Nation (Cameron Bisset)Leave a Comment

valneva logo

April 10, 2014

European biotechnology company Valneva SE (Valneva) announced today that it has granted vaccine manufacturer Adimmune Corporation certain exclusive rights to its Japanese encephalitis (JE) vaccine in Taiwan.

Adimmune will be entitled to register and commercialize Valneva´s JE vaccine under a local trade name and to develop, manufacture and commercialize such a vaccine from bulk product delivered by Valneva.

Japanese Encephalitis is recognized as a major public health issue in Asia, as evidenced by its inclusion into the national vaccination schedules of many endemic countries in Asia including Taiwan. Adimmune has worked with the Taiwanese Center for Disease Control and Prevention for decades to ensure supply of its mouse-brain derived JE vaccine, for which public tenders have historically reached a level of 600,000 doses per year. The Taiwanese Advisory Committee on Immunization Practices (ACIP) has recently recommended the introduction of a modern, cell-culture derived vaccine.

Adimmune will be entitled to register and commercialize Valneva´s JE vaccine under a local trade name and to develop, manufacture and commercialize such a vaccine from bulk product delivered by Valneva.

Japanese Encephalitis is recognized as a major public health issue in Asia, as evidenced by its inclusion into the national vaccination schedules of many endemic countries in Asia including Taiwan. Adimmune has worked with the Taiwanese Center for Disease Control and Prevention for decades to ensure supply of its mouse-brain derived JE vaccine, for which public tenders have historically reached a level of 600,000 doses per year. The Taiwanese Advisory Committee on Immunization Practices (ACIP) has recently recommended the introduction of a modern, cell-culture derived vaccine.

Thomas Lingelbach, President and Chief Executive Officer and Franck Grimaud, President and Chief Business Officer of Valneva commented, “This agreement is an important step forward in the execution of our JE vaccine expansion strategy into endemic markets. Given Adimmune`s leading position as a commercial vaccine manufacturer in Taiwan, we expect a significant requirement for future product supplies in this market, which will allow us to leverage our existing manufacturing capacities and significantly contribute to product profitability”.

Admmune will be responsible for assuming costs related to the development and registration of the vaccine in Taiwan.

Financial terms for the delivery of the vaccine by Valneva were not disclosed.

Leave a Comment

Current ye@r *